117 related articles for article (PubMed ID: 11078333)
21. Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist.
Sudoh K; Yuyama H; Noguchi Y; Fujimori A; Ukai M; Ohtake A; Sato S; Sasamata M; Miyata K
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S390-3. PubMed ID: 15838329
[TBL] [Abstract][Full Text] [Related]
22. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure.
Mulder P; Boujedaini H; Richard V; Derumeaux G; Henry JP; Renet S; Wessale J; Opgenorth T; Thuillez C
Circulation; 2000 Aug; 102(5):491-3. PubMed ID: 10920058
[TBL] [Abstract][Full Text] [Related]
23. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
Liu G; Henry KJ; Szczepankiewicz BG; Winn M; Kozmina NS; Boyd SA; Wasicak J; von Geldern TW; Wu-Wong JR; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
J Med Chem; 1998 Aug; 41(17):3261-75. PubMed ID: 9703472
[TBL] [Abstract][Full Text] [Related]
24. Coronary vascular reactivity is improved by endothelin A receptor blockade in DOCA-salt hypertensive rats.
Giulumian AD; Pollock DM; Clarke N; Fuchs LC
Am J Physiol; 1998 Jun; 274(6):R1613-8. PubMed ID: 9608015
[TBL] [Abstract][Full Text] [Related]
25. Endothelin a receptor blockade and endothelin B receptor blockade improve hypokalemic nephropathy by different mechanisms.
Suga S; Yasui N; Yoshihara F; Horio T; Kawano Y; Kangawa K; Johnson RJ
J Am Soc Nephrol; 2003 Feb; 14(2):397-406. PubMed ID: 12538740
[TBL] [Abstract][Full Text] [Related]
26. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats.
Matsumura Y; Hashimoto N; Taira S; Kuro T; Kitano R; Ohkita M; Opgenorth TJ; Takaoka M
Hypertension; 1999 Feb; 33(2):759-65. PubMed ID: 10024341
[TBL] [Abstract][Full Text] [Related]
27. Endothelin and ET(A) receptors in long-term arterial pressure homeostasis in conscious nonhuman primates.
Reinhart GA; Preusser LC; Opgenorth TJ; Wegner CD; Cox BF
Am J Physiol Regul Integr Comp Physiol; 2000 Nov; 279(5):R1701-6. PubMed ID: 11049852
[TBL] [Abstract][Full Text] [Related]
28. Pharmacology of L-744,453, a novel nonpeptidyl endothelin antagonist.
Williams DL; Murphy KL; Nolan NA; O'Brien JA; Lis EV; Pettibone DJ; Clineschmidt BV; Krause SM; Veber DF; Naylor EM; Chakravarty PK; Walsh TF; Dhanoa DM; Chen A; Bagley SW; Fitch KJ; Greenlee WJ
Life Sci; 1996; 58(14):1149-57. PubMed ID: 8614266
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083.
Douglas SA; Nambi P; Gellai M; Luengo JI; Xiang JN; Brooks DP; Ruffolo RR; Elliott JD; Ohlstein EH
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S273-6. PubMed ID: 9595458
[TBL] [Abstract][Full Text] [Related]
30. Use of A-192621 to provide evidence for involvement of endothelin ET(B)-receptors in endothelin-1-mediated cardiomyocyte hypertrophy.
Cullen JP; Bell D; Kelso EJ; McDermott BJ
Eur J Pharmacol; 2001 Apr; 417(3):157-68. PubMed ID: 11334846
[TBL] [Abstract][Full Text] [Related]
31. Evidence for two endothelin Et(A) receptor subtypes in rabbit arteriolar smooth muscle.
Curtis TM; Scholfield CN
Br J Pharmacol; 2001 Dec; 134(8):1787-95. PubMed ID: 11739256
[TBL] [Abstract][Full Text] [Related]
32. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
Li JS; Turgeon A; Schiffrin EL
Am J Hypertens; 1998 May; 11(5):554-62. PubMed ID: 9633791
[TBL] [Abstract][Full Text] [Related]
33. Different contributions of endothelin-A and endothelin-B receptors in postischemic cardiac dysfunction and norepinephrine overflow in rat hearts.
Yamamoto S; Matsumoto N; Kanazawa M; Fujita M; Takaoka M; Gariepy CE; Yanagisawa M; Matsumura Y
Circulation; 2005 Jan; 111(3):302-9. PubMed ID: 15642760
[TBL] [Abstract][Full Text] [Related]
34. Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists.
Watts SW; Fink GD; Northcott CA; Galligan JJ
Br J Pharmacol; 2002 Sep; 137(1):69-79. PubMed ID: 12183332
[TBL] [Abstract][Full Text] [Related]
35. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats.
Chen SJ; Chen YF; Opgenorth TJ; Wessale JL; Meng QC; Durand J; DiCarlo VS; Oparil S
J Cardiovasc Pharmacol; 1997 Jun; 29(6):713-25. PubMed ID: 9234651
[TBL] [Abstract][Full Text] [Related]
36. Role of ET(A) receptors in experimental ANG II-induced hypertension in rats.
Ballew JR; Fink GD
Am J Physiol Regul Integr Comp Physiol; 2001 Jul; 281(1):R150-4. PubMed ID: 11404288
[TBL] [Abstract][Full Text] [Related]
37. NADPH oxidase-derived superoxide augments endothelin-1-induced venoconstriction in mineralocorticoid hypertension.
Li L; Watts SW; Banes AK; Galligan JJ; Fink GD; Chen AF
Hypertension; 2003 Sep; 42(3):316-21. PubMed ID: 12885792
[TBL] [Abstract][Full Text] [Related]
38. Prevention of endothelin-1-induced increases in blood pressure: role of endogenous CGRP.
Wang Y; Wang DH
Am J Physiol Heart Circ Physiol; 2004 Oct; 287(4):H1868-74. PubMed ID: 15205172
[TBL] [Abstract][Full Text] [Related]
39. Hypertension induced by blockade of ET(B) receptors in conscious nonhuman primates: role of ET(A) receptors.
Reinhart GA; Preusser LC; Burke SE; Wessale JL; Wegner CD; Opgenorth TJ; Cox BF
Am J Physiol Heart Circ Physiol; 2002 Oct; 283(4):H1555-61. PubMed ID: 12234809
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological characterization of TA-0201, an endothelin receptor antagonist, with recombinant and human prostate endothelin receptors.
Takahashi M; Taniguchi T; Tanaka T; Kanamaru H; Okada K; Muramatsu I
Eur J Pharmacol; 2003 Apr; 467(1-3):185-9. PubMed ID: 12706473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
